HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES
HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES
Hinterlegungsschein · US44842L1035 · HCM · A2AF74 (XNAS)
Übersicht
15,35 USD
0,59 % 0,09 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 20:00

Aktuelle Kurse von HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
HCM
USD
06.06.2025 20:00
15,35 USD
15,26 USD
+0,59 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 10,04 % 4,14 % -4,15 % -10,02 % -16,76 % -33,23 %

Firmenprofil zu HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES Hinterlegungsschein

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

Investierte Fonds

Folgende Fonds haben in investiert: HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
74,80
Anteil (%)
0,18 %
Fonds
iShares MSCI China UCITS ETF USD (Dist)
Vol. in Mio
4,05
Anteil (%)
0,12 %
Fonds
iShares MSCI AC Far East ex-Japan UCITS ETF USD (Acc)
Vol. in Mio
11,75
Anteil (%)
0,05 %
Fonds
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)
Vol. in Mio
635,18
Anteil (%)
0,04 %
Fonds
iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)
Vol. in Mio
125,47
Anteil (%)
0,04 %

Unternehmensdaten

Name HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES
Firma HUTCHMED (China) Limited
Symbol HCM
Website https://www.hutch-med.com
Heimatbörse XNAS NASDAQ
WKN A2AF74
ISIN US44842L1035
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Drug Manufacturers - Specialty & Generic
CEO Dr. Wei-Guo Su B.Sc., Ph.D.
Marktkapitalisierung 2 Mrd.
Land Hongkong
Währung USD
Mitarbeiter 1,8 T
Adresse Cheung Kong Center, Central
IPO Datum 2016-03-16

Aktien-Splits

Datum Split
30.05.2019 10:1

Ticker Symbole

Name Symbol
Frankfurt H7T1.F
NASDAQ HCM

Weitere Aktien

Investoren die HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHARES die halten, haben auch folgende Aktien im Depot:
LYONDELLBASELL INDUSTRIES NV
LYONDELLBASELL INDUSTRIES NV Aktie
SOC.GEN.SFH 18/26 MTN
SOC.GEN.SFH 18/26 MTN Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025